GILD - Gilead Sciences Inc Stock Price, Fair Value and News

64.95USD+0.03 (+0.05%)Delayed as of 09 May 2024, 10:54 am ET

Market Summary

USD64.95+0.03

Delayedas of 09 May 2024, 10:54 am

0.05%

GILD Alerts

1 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

GILD Stock Price

View Fullscreen

GILD RSI Chart

GILD Valuation

Market Cap

80.9B

Price/Earnings (Trailing)

166.89

Price/Sales (Trailing)

2.95

EV/EBITDA

40.78

Price/Free Cashflow

10.23

GILD Price/Sales (Trailing)

GILD Profitability

EBT Margin

3.91%

Return on Equity

2.78%

Return on Assets

0.86%

Free Cashflow Yield

9.77%

GILD Fundamentals

GILD Revenue

Revenue (TTM)

27.4B

Rev. Growth (Yr)

5.26%

Rev. Growth (Qtr)

-6.02%

GILD Earnings

Earnings (TTM)

484.5M

Earnings Growth (Yr)

-512.87%

Earnings Growth (Qtr)

-391.71%

Breaking Down GILD Revenue

52 Week Range

64.7281.43

(Low)(High)

Last 7 days

-0.9%

Last 30 days

-6.5%

Last 90 days

-12.1%

Trailing 12 Months

-17.6%

How does GILD drawdown profile look like?

GILD Financial Health

Current Ratio

1.08

Debt/Equity

1.23

Debt/Cashflow

0.39

GILD Investor Care

Dividend Yield

4.65%

Dividend/Share (TTM)

3.02

Buy Backs (1Y)

0.12%

Diluted EPS (TTM)

0.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	27.4B	0	0	0
2023	27.0B	27.4B	27.4B	27.1B
2022	27.5B	27.5B	27.1B	27.3B
2021	25.6B	26.6B	27.5B	27.3B
2020	22.7B	22.2B	23.1B	24.7B
2019	22.3B	22.4B	22.4B	22.4B
2018	24.7B	23.2B	22.3B	22.1B
2017	29.1B	28.5B	27.5B	26.1B
2016	32.8B	32.4B	31.6B	30.4B
2015	27.5B	29.2B	31.4B	32.6B
2014	13.7B	17.4B	20.7B	24.9B
2013	10.0B	10.3B	10.7B	11.2B
2012	8.7B	9.0B	9.3B	9.7B
2011	7.8B	8.0B	8.2B	8.4B
2010	7.6B	7.8B	8.0B	7.9B
2009	5.6B	6.0B	6.4B	7.0B
2008	0	4.6B	5.0B	5.3B
2007	0	0	0	4.2B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Gilead Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 25, 2024	telman deborah h	acquired	-	-	515	evp, corporate affairs & gc
Apr 25, 2024	telman deborah h	sold (taxes)	-10,312	65.27	-158	evp, corporate affairs & gc
Apr 01, 2024	parsey merdad	sold	-145,920	72.96	-2,000	chief medical officer
Mar 10, 2024	patterson sandra	acquired	-	-	2,682	svp, controllership
Mar 10, 2024	mercier johanna	sold (taxes)	-342,472	75.12	-4,559	chief commercial officer
Mar 10, 2024	mercier johanna	acquired	-	-	9,844	chief commercial officer
Mar 10, 2024	telman deborah h	sold (taxes)	-63,551	75.12	-846	evp, corporate affairs & gc
Mar 10, 2024	parsey merdad	acquired	-	-	10,401	chief medical officer
Mar 10, 2024	dickinson andrew d	sold (taxes)	-338,416	75.12	-4,505	chief financial officer
Mar 10, 2024	telman deborah h	acquired	-	-	2,555	evp, corporate affairs & gc

Which funds bought or sold GILD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Pillar Wealth Advisors, LLC	unchanged	-	-80,456	759,456	0.57%
May 07, 2024	Illinois Municipal Retirement Fund	added	0.13	-1,835,000	17,555,000	0.27%
May 07, 2024	Meeder Advisory Services, Inc.	added	5.81	-72,925	1,612,770	0.16%
May 07, 2024	THOROUGHBRED FINANCIAL SERVICES, LLC	sold off	-100	-217,000	-	-%
May 07, 2024	Empirical Financial Services, LLC d.b.a. Empirical Wealth Management	added	15.38	348,621	8,412,000	0.25%
May 07, 2024	RIVER GLOBAL INVESTORS LLP	reduced	-1.11	-147,665	1,244,420	0.31%
May 07, 2024	WestEnd Advisors, LLC	added	5.26	-74.00	1,465	-%
May 07, 2024	Bank Pictet & Cie (Europe) AG	unchanged	-	-101,074	954,081	0.03%
May 07, 2024	PFG Advisors	reduced	-7.94	-44,410	220,717	0.02%
May 07, 2024	Skopos Labs, Inc.	sold off	-100	-473,665	-	-%

Are Funds Buying or Selling GILD?

Are funds buying GILD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GILD

No. of Funds

Unveiling Gilead Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.97%	111,820,711	SC 13G/A
Feb 09, 2024	capital world investors	6.7%	83,698,215	SC 13G/A
Jan 24, 2024	blackrock inc.	9.9%	122,790,297	SC 13G/A
Feb 13, 2023	capital world investors	5.5%	68,900,998	SC 13G
Feb 13, 2023	capital research global investors	4.4%	54,602,952	SC 13G/A
Feb 09, 2023	vanguard group inc	8.93%	112,038,324	SC 13G/A
Jan 31, 2023	blackrock inc.	10.5%	131,555,769	SC 13G/A
Jul 08, 2022	blackrock inc.	10.1%	126,932,693	SC 13G
Feb 11, 2022	capital research global investors	8.5%	107,156,981	SC 13G/A
Feb 10, 2022	vanguard group inc	8.43%	105,803,799	SC 13G/A

Recent SEC filings of Gilead Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 02, 2024	SC 13D/A	13D - Major Acquisition
Apr 26, 2024	4	Insider Trading
Apr 25, 2024	8-K	Current Report
Apr 19, 2024	3	Insider Trading
Apr 19, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	SC 13G	Major Ownership Report
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Gilead Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	358.5B	85.6B	-1.74%	-7.51%	9.32	4.19	5.68%	202.39%
MRK	328.0B	61.4B	2.34%	10.30%	142.26	5.34	6.11%	-82.30%
AMGN	164.9B	29.5B	14.19%	31.13%	43.82	5.58	12.76%	-52.47%
PFE	160.3B	57.8B	6.40%	-25.71%	127.84	2.77	76.51%	-86.81%
GILD	80.9B	27.4B	-6.51%	-17.64%	166.89	2.95	1.51%	-91.32%
TEVA	17.8B	16.0B	10.77%	72.86%	-36.05	1.11	7.23%	71.10%
MID-CAP
PRGO	4.2B	4.6B	-2.02%	-10.81%	-550.77	0.93	-0.06%	94.55%
ALKS	4.1B	1.7B	-7.02%	-22.02%	9.39	2.36	54.01%	364.56%
BHC	2.6B	9.0B	-27.55%	19.80%	-5.67	0.29	10.01%	-27.45%
AMPH	2.0B	644.4M	2.87%	15.89%	14.76	3.15	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-25.10%	-28.68%	-4.27	2.02	24.65%	80.36%
TXMD	23.3M	1.3M	-6.48%	-47.40%	-2.27	17.89	-98.14%	-109.18%
ACRX	17.5M	-	-11.21%	50.12%	-0.95	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	5.13%	-93.31%	-0.19	0.14	80.00%	43.08%
ACOR	968.8K	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Gilead Sciences Inc News

Latest updates

Gilead Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-6.0%	6,686	7,114	7,051	6,599	6,352	7,389	7,042	6,260	6,590	7,244	7,421	6,217	6,423	7,421	6,577	5,143	5,548	5,879	5,604	5,685	5,281
Costs and Expenses	100.1%	11,008	5,502	4,428	4,934	4,647	5,122	4,205	4,231	6,393	6,304	3,579	3,971	3,533	4,770	4,576	8,126	3,146	4,786	7,077	3,255	3,044
S&GA Expenses	-14.5%	1,375	1,608	1,315	1,849	1,319	2,020	1,213	1,357	1,083	1,650	1,190	1,351	1,055	1,730	1,106	1,239	1,076	1,204	1,052	1,095	1,030
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,101	1,899	4,990	1,160	1,057
EBITDA Margin	-71.0%	0.09*	0.30*	0.31*	0.31*	0.32*	0.26*	0.21*	0.25*	0.26*	0.35*	0.39*	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.8%	254	252	232	230	230	226	229	242	238	238	250	256	257	267	236	240	241	243	250	248	254
Income Taxes	-233.2%	-315	237	146	549	316	398	646	368	-164	383	852	300	542	270	472	373	465	-788	-333	535	382
Earnings Before Taxes	-371.4%	-4,486	1,653	2,318	1,588	1,300	2,031	2,432	1,503	-152	759	3,438	1,817	2,264	1,814	825	-2,973	2,003	1,901	-1,501	2,410	2,350
EBT Margin	-84.5%	0.04*	0.25*	0.26*	0.27*	0.27*	0.21*	0.17*	0.20*	0.21*	0.30*	0.34*	-	-	-	-	-	-	-	-	-	-
Net Income	-391.7%	-4,170	1,430	2,180	1,045	1,010	1,640	1,789	1,144	19.00	382	2,592	1,522	1,729	1,551	360	-3,339	1,551	2,696	-1,165	1,880	1,975
Net Income Margin	-91.6%	0.02*	0.21*	0.21*	0.20*	0.21*	0.17*	0.12*	0.15*	0.16*	0.23*	0.27*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	8.2%	2,114	1,954	1,633	2,199	1,635	2,386	2,706	1,659	1,593	3,049	3,114	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.4%	56,292	62,125	62,373	62,337	61,876	63,171	62,557	62,870	63,080	67,952	67,098	67,984	67,492	68,407	60,878	55,934	59,741	61,627	59,146	63,210	62,837
Current Assets	-12.7%	14,041	16,085	15,980	14,287	13,456	14,443	13,554	13,175	12,629	14,772	13,991	13,925	13,278	15,996	30,926	24,643	26,950	30,296	28,361	33,727	34,024
Cash Equivalents	-22.5%	4,718	6,085	5,705	5,704	4,936	5,412	4,699	4,739	4,296	5,338	4,362	4,893	4,065	5,997	12,886	6,746	10,051	11,631	9,474	11,240	16,927
Inventory	3.7%	1,853	1,787	1,663	1,633	1,576	1,507	1,463	1,494	1,482	1,618	1,676	1,772	1,779	1,683	1,008	1,052	986	922	882	884	898
Net PPE	0.1%	5,321	5,317	5,572	5,540	5,479	5,475	5,349	5,299	5,253	5,121	5,037	4,996	4,990	4,967	4,810	4,653	4,564	4,502	4,377	4,249	4,116
Goodwill	0%	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,332	8,332	8,334	8,334	8,108	4,117	4,117	4,117	4,117	4,117	4,117	4,117
Current Liabilities	15.4%	13,015	11,280	11,945	13,964	10,528	11,237	10,423	9,220	8,558	11,610	10,245	10,214	9,705	11,397	9,509	10,564	8,879	9,759	9,567	8,961	9,397
Long Term Debt	-7.2%	21,527	23,189	23,189	21,209	22,956	22,957	22,953	25,195	25,183	25,179	25,175	27,914	27,907	28,645	27,792	21,103	22,098	22,094	22,090	24,084	24,080
LT Debt, Non Current	-100.0%	-	23,189	23,189	21,209	22,956	22,957	22,953	25,195	25,183	25,179	25,175	27,914	27,907	28,645	27,792	21,103	22,098	22,094	22,090	24,084	24,080
Shareholder's Equity	-23.6%	17,455	22,833	22,314	21,094	20,939	21,240	21,057	20,215	19,915	21,064	21,471	19,710	18,964	18,221	17,471	18,142	22,179	22,650	20,736	22,751	22,091
Retained Earnings	-34.6%	10,656	16,304	16,002	15,138	15,223	15,687	15,756	15,117	14,986	16,324	16,903	15,392	14,821	14,381	13,709	14,445	18,709	19,388	17,616	19,829	19,326
Additional Paid-In Capital	4.8%	6,813	6,500	6,279	6,008	5,793	5,550	5,226	5,031	4,867	4,661	4,492	4,271	4,092	3,880	3,712	3,511	3,311	3,051	2,870	2,684	2,494
Shares Outstanding	0%	1,246	1,246	1,247	1,247	1,248	1,247	1,255	1,256	1,255	1,256	1,256	1,256	-	-	-	-	-	-	-	-	-
Minority Interest	0%	-84.00	-84.00	-72.00	-64.00	-58.00	-31.00	-24.00	-21.00	-12.00	-5.00	1.00	7.00	12.00	19.00	26.00	115	112	125	132	135	140
Float	-	-	-	-	67,000	-	-	-	55,900	-	-	-	62,600	-	-	-	69,900	-	-	-	66,400	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	2.3%	2,219	2,169	1,755	2,338	1,744	2,567	2,863	1,802	1,840	3,205	3,253	2,316	2,610	1,916	2,250	2,566	1,436	2,580	2,645	2,342	1,577
Share Based Compensation	-7.0%	187	201	202	198	165	174	168	165	130	159	171	166	139	161	173	168	141	157	162	174	143
Cashflow From Investing	-203.6%	-2,207	-727	-229	-483	-826	-375	-713	-308	-1,070	-278	-234	-577	-2,042	-8,977	-271	-5,023	-344	431	-1,841	-6,163	-244
Cashflow From Financing	-23.8%	-1,361	-1,099	-1,519	-1,101	-1,406	-1,554	-2,118	-1,003	-1,794	-1,942	-3,527	-931	-2,477	131	4,124	-874	-2,611	-896	-2,515	-1,857	-2,366
Dividend Payments	-100.0%	-	943	953	944	969	915	929	920	945	894	900	894	917	858	861	856	874	801	804	800	817
Buy Backs	166.7%	400	150	300	150	400	792	182	70.00	352	27.00	183	49.00	309	-22.50	238	62.00	1,328	88.00	252	593	834

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GILD Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 27,116	$ 27,281	$ 27,305
Costs and expenses:
Cost of goods sold	6,498	5,657	6,601
Research and development expenses	5,718	4,977	4,601
Acquired in-process research and development expenses	1,155	944	939
In-process research and development impairments	50	2,700	0
Selling, general and administrative expenses	6,090	5,673	5,246
Total costs and expenses	19,511	19,951	17,387
Operating income	7,605	7,330	9,918
Interest expense	(944)	(935)	(1,001)
Other income (expense), net	198	(581)	(639)
Income before income taxes	6,859	5,814	8,278
Income tax expense	(1,247)	(1,248)	(2,077)
Net income	5,613	4,566	6,201
Net loss attributable to noncontrolling interest	52	26	24
Net income attributable to Gilead	$ 5,665	$ 4,592	$ 6,225
Basic earnings per share attributable to Gilead (in dollars per share)	$ 4.54	$ 3.66	$ 4.96
Shares used in basic earnings per share attributable to Gilead calculation (in shares)	1,248	1,255	1,256
Diluted earnings per share attributable to Gilead (in dollars per share)	$ 4.50	$ 3.64	$ 4.93
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)	1,258	1,262	1,262
Product sales
Revenues:
Total revenues	$ 26,934	$ 26,982	$ 27,008
Royalty, contract and other revenues
Revenues:
Total revenues	$ 182	$ 299	$ 297

GILD Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,085	$ 5,412
Short-term marketable debt securities	1,179	973
Accounts receivable, net	4,660	4,777
Inventories	1,787	1,507
Prepaid and other current assets	2,374	1,774
Total current assets	16,085	14,443
Property, plant and equipment, net	5,317	5,475
Long-term marketable debt securities	1,163	1,245
Intangible assets, net	26,454	28,894
Goodwill	8,314	8,314
Other long-term assets	4,792	4,800
Total assets	62,125	63,171
Current liabilities:
Accounts payable	550	905
Accrued rebates	3,802	3,479
Other current liabilities	5,130	4,580
Current portion of long-term debt and other obligations, net	1,798	2,273
Total current liabilities	11,280	11,237
Long-term debt, net	23,189	22,957
Long-term income taxes payable	2,039	3,916
Deferred tax liability	1,588	2,673
Other long-term obligations	1,280	1,179
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding	0	0
Common stock, par value $0.001 per share; 5,600 authorized; 1,246 and 1,247 shares issued and outstanding, respectively	1	1
Additional paid-in capital	6,500	5,550
Accumulated other comprehensive income	28	2
Retained earnings	16,304	15,687
Total Gilead stockholders’ equity	22,833	21,240
Noncontrolling interest	(84)	(31)
Total stockholders’ equity	22,749	21,209
Total liabilities and stockholders’ equity	$ 62,125	$ 63,171

About Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

CEO	Mr. Daniel P. O'Day
WEBSITE	gilead.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	17000

Gilead Sciences Inc Frequently Asked Questions

What is the ticker symbol for Gilead Sciences Inc? What does GILD stand for in stocks?

GILD is the stock ticker symbol of Gilead Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gilead Sciences Inc (GILD)?

As of Wed May 08 2024, market cap of Gilead Sciences Inc is 80.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GILD stock?

You can check GILD's fair value in chart for subscribers.

What is the fair value of GILD stock?

You can check GILD's fair value in chart for subscribers. The fair value of Gilead Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gilead Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GILD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gilead Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether GILD is over valued or under valued. Whether Gilead Sciences Inc is cheap or expensive depends on the assumptions which impact Gilead Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GILD.

What is Gilead Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, GILD's PE ratio (Price to Earnings) is 166.89 and Price to Sales (PS) ratio is 2.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GILD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Gilead Sciences Inc's stock?

In the past 10 years, Gilead Sciences Inc has provided 0.006 (multiply by 100 for percentage) rate of return.